NE-3107 is under clinical development by BioVie and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NE-3107’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BioVie (BIVI) is a clinical-stage biopharmaceutical company that develops drug therapies for liver disease. The company’s pipeline products such as BIV201 (continuous infusion terlipressin) and clinical trial for ascites due to advanced liver cirrhosis. BIV201 for hepatorenal syndrome (HRS). It focused on potential future treatment option patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, NASH and alcoholism. The company is also focused on the FDA to approve their drug specifically for treating ascites to extend their quality. BioVie is targeting this landmark achievement. BIVI is headquartered in Santa Monica, California, the US.
For a complete picture of NE-3107’s drug-specific PTSR and LoA scores, buy the report here.